Evidence map›Paper›PMID 39612123›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

Rotenone adaptation promotes migration and invasion of p53-wild-type colon cancer through lipid metabolism.

Yingying Shi, Zhen Cao, Ling Ge, Lin Lei, Dan Tao, Juan Zhong, Dan Xu, Tao Geng, Xuetao Li, Ziwei Li and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yingying ShiDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China.
Zhen CaoDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China.
Ling GeDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China.
Lin LeiDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China.
Dan TaoDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China.
Juan ZhongDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China.
Dan XuDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China.
Tao GengDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China.
Xuetao LiDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China.
Ziwei LiDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China.
Shuaishuai XingDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China.
Xinyu WuDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China.
Zhongxu WangDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China.
Linjun LiDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Wuhan, 430070, China. lilinjun00417@126.com.ORCID http://orcid.org/0009-0004-2944-7225

Funding

Natural Science Foundation of Hubei Province 2024AFB533Scientific Research Fund of Maternal and Child Health Hospital of Hubei Province 2021SFYM002
6 · The paper itself

Abstract

backgroundThe association between mitochondrial dysfunction and multiple metabolic adaptations is increasingly being proven. We previously elucidated that mitochondrial complex I deficiency can promote glycolysis in mut-p53 SW480 cells. However, studies have revealed a phenotype with attenuated glycolysis but enhanced fatty acid oxidation (FAO) in invasive tumors. The interplay between complex I and FAO in carcinogenesis remains obscure.

methodsThe p53 wild-type RKO cells were exposed to rotenone over at least 2 months to acquire rotenone adaptation cells. Then the transwell invasion assays and expression of metabolic enzymes were first detected in rotenone adaptation cells to illustrate whether rotenone adaptation is correlated with the invasion and FAO. The levels of epithelial-to-mesenchymal transition (EMT)-related proteins and acetyl-CoA in rotenone adaptation cells treated with etomoxir (ETO) and acetate were evaluated to verify the role of CPT1A in regulating invasion. Finally, the levels of reactive oxygen species (ROS) were detected. Meanwhile, the invasiveness and histone acetylation levels of rotenone adaptation cells were observed after adding an ROS inhibitor (N-acetyl-L-cysteine NAC) to demonstrate the molecular connection between FAO and invasion during rotenone adaptation.

resultsWe found long-term exposure to rotenone (a mitochondrial complex I inhibitor) led to EMT and high CPT1A expression in wt-p53 colon cancer. The inhibition of CPT1A suppressed the invasion and reduced histone acetylation, which was rescued by supplementing with acetate. Mechanistically, ROS is crucial for lipid metabolism remodeling.

conclusionOur study provides a novel understanding of the role of complex I in lipid reprogramming facilitating colon cancer invasion and metastasis.

Indexed as

Cell MovementColonic NeoplasmsLipid MetabolismRotenoneTumor Suppressor Protein p53Carnitine O-PalmitoyltransferaseCell Line, TumorElectron Transport Complex IEpithelial-Mesenchymal TransitionEpoxy CompoundsHumansNeoplasm InvasivenessReactive Oxygen SpeciesCarnitine O-PalmitoyltransferaseCPT1A protein, humanElectron Transport Complex IEpoxy CompoundsetomoxirReactive Oxygen SpeciesRotenoneTumor Suppressor Protein p53CPT1AHistone acetylationMigration and invasionMitochondrial complex IRotenone

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.